Literature DB >> 3391682

Hypertensive mechanisms associated with centrally administered aldosterone in dogs.

Y Kageyama1, E L Bravo.   

Abstract

The mechanism by which intracerebroventricularly administered aldosterone increases arterial pressure was investigated in trained, conscious dogs with cannulas chronically implanted in a lateral cerebral ventricle. In salt-replete and salt-depleted dogs, artificial cerebrospinal fluid with or without aldosterone (0.05 microgram/kg/hr) was infused intracerebroventricularly for 12 days by an osmotic minipump. A similar dose of aldosterone was infused subcutaneously for 12 days. Aldosterone infused intracerebroventricularly increased blood pressure significantly in both salt-replete and salt-depleted dogs. In salt-replete animals the hypertension was associated with increased total peripheral resistance without concomitant changes in blood volume, cardiac output, or in any of the neurohumoral parameters measured. We conclude that this type of hypertension is resistance-mediated from its outset and appears to be relatively independent of salt and water retention. The mechanism by which intracerebroventricularly administered aldosterone increases vascular resistance remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3391682     DOI: 10.1161/01.hyp.11.6.750

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  14 in total

Review 1.  Role of central mineralocorticoid receptors in cardiovascular disease.

Authors:  C E Gomez-Sanchez; E P Gomez-Sanchez
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

2.  Effect of intracerebroventricular benzamil on cardiovascular and central autonomic responses to DOCA-salt treatment.

Authors:  Joanna M Abrams; William C Engeland; John W Osborn
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-10-06       Impact factor: 3.619

Review 3.  Aldosterone in the brain.

Authors:  Joel C Geerling; Arthur D Loewy
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-04

4.  Mineralocorticoid receptor antagonists attenuate exaggerated exercise pressor reflex responses in hypertensive rats.

Authors:  Ryan M Downey; Masaki Mizuno; Jere H Mitchell; Wanpen Vongpatanasin; Scott A Smith
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-07-21       Impact factor: 4.733

5.  Efficacy of selective mineralocorticoid and glucocorticoid agonists in canine septic shock.

Authors:  Caitlin W Hicks; Daniel A Sweeney; Robert L Danner; Peter Q Eichacker; Anthony F Suffredini; Jing Feng; Junfeng Sun; Ellen N Behrend; Steven B Solomon; Charles Natanson
Journal:  Crit Care Med       Date:  2012-01       Impact factor: 7.598

Review 6.  Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism.

Authors:  I David Weiner
Journal:  Semin Nephrol       Date:  2013-05       Impact factor: 5.299

7.  Raised urinary glucocorticoid and adrenal androgen precursors in the urine of young hypertensive patients: possible evidence for partial glucocorticoid resistance.

Authors:  W Shamim; M Yousufuddin; D P Francis; P Gualdiero; J W Honour; S D Anker; A J Coats
Journal:  Heart       Date:  2001-08       Impact factor: 5.994

Review 8.  A role for benzamil-sensitive proteins of the central nervous system in the pathogenesis of salt-dependent hypertension.

Authors:  Joanna M Abrams; John W Osborn
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-05       Impact factor: 2.557

9.  Effect of global and regional sympathetic blockade on arterial pressure during water deprivation in conscious rats.

Authors:  Britta J Veitenheimer; William C Engeland; Pilar A Guzman; Gregory D Fink; John W Osborn
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-17       Impact factor: 4.733

10.  Sex differences and central protective effect of 17beta-estradiol in the development of aldosterone/NaCl-induced hypertension.

Authors:  Baojian Xue; Daniel Badaue-Passos; Fang Guo; Celso E Gomez-Sanchez; Meredith Hay; Alan Kim Johnson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-06       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.